Figure 6.

Plasma concentrations of deoxyribonucleosides, urinary excretion of deoxyribonucleosides, body weight and plasma creatine kinase in Patient 2 between 27 and 76 months of therapy with EE-TP. (a) Intra-cycle plasma thymidine and deoxyuridine concentrations were measured by UPLC. (b) Intra-cycle urinary excretions of thymidine and deoxyuridine were determined by measuring the concentration of the metabolites in 24 h urine collections. Red dotted lines represent pre-therapy deoxyuridine plasma concentration and urinary excretion, and blue dotted lines represent pre-therapy thymidine plasma concentrations and urinary excretion. (c) Patient body weight. (d) Plasma creatine kinase activity. Pink dotted line represents pre-therapy activity.